RSLS ReShape Lifesciences Inc: Aset Agregat Bisnis

ReShape Lifesciences (RSLS) relies on diversified US supply chains, which minimizes logistical risks and supports margins. This price action reflects the current total asset volume at 7.71. Business stability is ensured by local manufacturing plants for weight loss systems and FDA certification. The company is currently undergoing a merger with a niche developer, focusing on resource integration.

Total Aset Perusahaan reshapelifesciences.com (RSLS): kanggo periode 04.07.2022 - 30.08.2025

Rincian metrik keuangan lan pasar reshapelifesciences.com (RSLS)

- rega lan prakiraan konsensus rega:

Bagan bursa ReShape Lifesciences Inc.|RSLS - Target konsensus

- data kapitalisasi pasar:

Nilai pasar ReShape Lifesciences|RSLS - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi Saham ReShape Lifesciences|RSLS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku reshapelifesciences.com|RSLS - Aset Agregat Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi ReShape Lifesciences|RSLS - Utang jangka dawa marang modal|Utang jangka cendhak marang modal ReShape Lifesciences Inc.|RSLS - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku ReShape Lifesciences|RSLS - Utang jangka dawa perusahaan|Utang jangka cendhak ReShape Lifesciences

Analisis fundamental perusahaan:ReShape Lifesciences

Produk asil prodhuksi reshapelifesciences.com

Specializing in safe gastric banding via the Lap-Band system, ReShape Lifesciences (RSLS) leverages its resources to scale reversible obesity surgery methods, a trend reflected in its total assets dynamics. This metric, calculated inversely through return on assets (ROA), measures the aggregate volume of capital and liabilities, allowing investors to assess asset management efficiency and the risks of diminishing returns as the balance sheet expands.

Perusahaan pesaing